Literature DB >> 8659425

Detecting hepatocellular carcinoma: value of unenhanced or arterial phase CT imaging or both used in conjunction with conventional portal venous phase contrast-enhanced CT imaging.

J H Oliver1, R L Baron, M P Federle, H E Rockette.   

Abstract

OBJECTIVE: Because rates of detection of hypervascular neoplasms by conventional dynamic incremental-bolus CT are lower than rates of detection of hypovascular tumors by CT and because both unenhanced CT imaging and arterial phase helical CT imaging may increase the detection of hypervascular tumors, such as hepatocellular carcinoma, we evaluated the value of unenhanced and arterial phase CT imaging used in conjunction with conventional portal venous phase CT imaging in patients with hepatocellular carcinoma.
MATERIALS AND METHODS: Unenhanced and biphasic helical contrast-enhanced CT studies were performed on 81 patients with proven hepatocellular carcinoma. Arterial phase and portal venous phase images were obtained at 20-50 sec and at 60-100 sec, respectively. Three blinded readers evaluated portal venous phase images for the number of liver lesions. On separate dates, the readers compared the arterial phase images with the portal venous phase images and the unenhanced images with the portal venous phase images. The readers recorded the number of lesions that were seen on portal venous phase images and that were also detected on unenhanced or arterial phase images as well as the number of additional lesions seen on unenhanced or arterial phase images. Consensus readings of unenhanced, arterial phase, and portal venous phase images were obtained in the 42 patients who had definitive surgery or follow-up CT scans, documenting the total tumor burden in this patient subgroup.
RESULTS: The readers identified 286-310 lesions on portal venous phase images. On unenhanced images, the readers identified 223-244 of the lesions seen on portal venous phase images and an additional 45-55 lesions that were not seen on portal venous phase images. Arterial phase imaging revealed 245-269 of the lesions seen on portal venous phase images and an additional 89-111 lesions that were not seen on portal venous images. The diagnosis of tumor was possible only on unenhanced images in two (3%) of 81 patients and only on arterial phase images in seven patients (9%). In the subset of 42 patients with proof of tumor burden, 157 proven lesions were found. Consensus readings identified 127 (81%) of these lesions on portal venous phase images, 98 (62%) of these lesions on unenhanced images, and 120 (76%) of these lesions on arterial phase images. Of the 30 lesions not seen on portal venous phase images, nine were seen on both unenhanced and arterial phase images, three were seen on unenhanced images only, and 18 were seen on arterial phase images only.
CONCLUSION: In patients with known or suspected hepatocellular carcinoma, the use of unenhanced or arterial phase images or both in addition to conventional portal venous phase images resulted in more tumors being detected. The combination of arterial phase and portal venous phase images revealed significantly more hepatocellular carcinoma lesions than did the combination of unenhanced and portal venous phase images.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8659425     DOI: 10.2214/ajr.167.1.8659425

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  21 in total

1.  Value of lipiodol computed tomography and digital subtraction angiography in the era of helical biphasic computed tomography as preoperative assessment of hepatocellular carcinoma.

Authors:  A Nakayama; H Imamura; Y Matsuyama; H Kitamura; S Miwa; A Kobayashi; S Miyagawa ; S Kawasaki
Journal:  Ann Surg       Date:  2001-07       Impact factor: 12.969

2.  Optimizing scan timing of hepatic arterial phase by physiologic pharmacokinetic analysis in bolus-tracking technique by multi-detector row computed tomography.

Authors:  Isao Yamaguchi; Eiji Kidoya; Masayuki Suzuki; Hirohiko Kimura
Journal:  Radiol Phys Technol       Date:  2010-09-25

3.  Assessment of Added Value of Noncontrast to Contrast-Enhanced Abdominal Computed Tomography Scan for Characterization of Hypervascular Liver Metastases.

Authors:  Gelareh Sadigh; Sadhna B Nandwana; Courtney Moreno; Kelly L Cox; Deborah A Baumgarten; Jeffrey Switchenko; Tiffany Easter; Kimberly E Applegate
Journal:  Curr Probl Diagn Radiol       Date:  2016-05-25

4.  [Multidetector computed tomography of the liver].

Authors:  W Schima; C Kulinna; A Ba-Ssalamah; T Grünberger
Journal:  Radiologe       Date:  2005-01       Impact factor: 0.635

5.  Detection of hypervascular hepatocellular carcinoma: Comparison of multi-detector CT with digital subtraction angiography and Lipiodol CT.

Authors:  Xiao-Hua Zheng; Yong-Song Guan; Xiang-Ping Zhou; Juan Huang; Long Sun; Xiao Li; Yuan Liu
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

Review 6.  Approaches to the diagnosis of hepatocellular carcinoma.

Authors:  Morris Sherman
Journal:  Curr Gastroenterol Rep       Date:  2005-02

7.  Current imaging strategies of primary and secondary neoplasms of the liver.

Authors:  Linda Fielding
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

8.  Role of multiphase scans by multirow-detector helical CT in detecting small hepatocellular carcinoma.

Authors:  Hong Zhao; Kang-Rong Zhou; Fu-Hua Yan
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

Review 9.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Authors:  An Tang; Mustafa R Bashir; Michael T Corwin; Irene Cruite; Christoph F Dietrich; Richard K G Do; Eric C Ehman; Kathryn J Fowler; Hero K Hussain; Reena C Jha; Adib R Karam; Adrija Mamidipalli; Robert M Marks; Donald G Mitchell; Tara A Morgan; Michael A Ohliger; Amol Shah; Kim-Nhien Vu; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-21       Impact factor: 11.105

10.  Diagnosis of hepatocellular carcinoma.

Authors:  Eldad S Bialecki; Adrian M Di Bisceglie
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.